Apaziquone
(for Intravesical Instillation)
Apaziquone is an investigational drug not yet approved by the FDA.
Apaziquone is a bioreductive agent activated by reductase enzymes, such as DT-diaphorase, expressed by bladder tumor cells, to form cytotoxic alkylating agents.
> To read about the latest news about apaziquone, or to learn more about its current development, click here.
Apaziquone is being investigated for intravesical instillation post-transurethral resection of bladder tumors (post-TURBT) in patients with non-muscle invasive bladder cancer (NMIBC).
Apaziquone is an investigational drug not yet approved by the FDA.
More About Apaziquone
Development Indications
Apaziquone is being investigated for intravesical instillation post-transurethral resection of bladder tumors
(post-TURBT) in patients with non-muscle invasive bladder cancer (NMIBC).
Latest News on Apaziquone
Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Apaziquone in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Read MoreFDA Advisory Committee Votes that Apaziquone Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo
Read MoreSpectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research Inc. (AUA) in San Diego, CA
Read MoreSpectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation)
Read MoreSpectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement
Read MoreSpectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Read MoreSpectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
Read MoreSpectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials
Read More